Abeona Therapeutics Reports Strong Commercial Momentum for ZEVASKYN Gene Therapy Launch

summarizeSummary

Abeona Therapeutics announced positive progress in the commercial launch of its FDA-approved gene therapy, ZEVASKYN, highlighting broad payer coverage and the establishment of a critical J-code for reimbursement.

check_boxKey Events

• ZEVASKYN Commercial Launch Progress

  Abeona Therapeutics reported building momentum in the commercial launch of its FDA-approved gene therapy, ZEVASKYN, for RDEB. The first patient was treated in December 2025, and manufacturing has resumed with additional patient treatments and biopsies in Q1 2026.

• Broad Payer Coverage Secured

  ZEVASKYN has achieved broad market acceptance with policies covering 80% of commercially insured lives from major payers and coverage across all Medicaid programs.

• Permanent J-Code Established

  The Centers for Medicare and Medicaid Services (CMS) established a permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J3389) for ZEVASKYN, effective January 1, 2026, which is vital for streamlining billing and reimbursement.

auto_awesomeAnalysis

This 8-K provides a positive business update on the commercial launch of ZEVASKYN, the company's FDA-approved gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Key developments include the completion of the first patient treatment in Q4 2025, resumed manufacturing and subsequent patient treatments in Q1 2026, and significant progress in market access. The establishment of a permanent J-code for ZEVASKYN and broad payer coverage (80% commercial, all Medicaid) are crucial for streamlining reimbursement and driving sustained demand, indicating a positive trajectory for the product's commercialization.